DIAGNOSIS AND TREATMENT OF TFE-REARRANGED RENAL CELL CARCINOMA

ASCO-endorsed webinar Date: September 9, 2026 TFE-rearranged renal cell carcinoma represents a distinct and challenging subtype of kidney cancer, requiring specialized diagnostic approaches and multidisciplinary management. Moderators: Ilya Tsimafeyeu, MD (USA/RU) - Salmat Kaldarbekov, MD (KZ) 00:00 Welcome message Sarah Bachmann, ASCO Representative Ilya Tsimafeyeu, Director, BUCARE 12:22 Radiation Oncology: Is TFE-rearranged RCC sensitive to radiation therapy? Timur Mitin, MD, PhD Professor, Radiation Oncologist, Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA 00:35 Pathology Insights: Diagnostic criteria, molecular features, and reporting standards. Maria Tretiakova, MD, PhD, FCAP Professor, President-elect, GUPS, GU pathology service chief, Director, GU pathology fellowship & HMC clerkship, Director, UWMC/HMC IHC laboratories, University of Washington, Seattle, WA, USA 01:00 Medical Oncology Perspectives: Systemic treatment strategies and emerging therapies. Kadriye Başkurt, MD, Medical Oncologist, Ankara Etlik City Hospital, Ankara, Turkey